Search Results

2026 GPCR Pharmacology AMA: Receptor Theory, Biased Signaling & Assay Interpretation The first GPCR Pharmacology AMA of 2026  at Terry’s Corner will take place on: Thursday, February 26 at 1 PM EST Dr. Kenakin will address receptor theory, assay interpretation, biased signaling, and practical drug discovery challenges — driven by questions from the community. These sessions focus on real scientific uncertainty, not rehearsed presentations. Terry’s Corner Expands to YouTube Terry’s Corner is now on YouTube. Three videos are already live, and the channel will expand regularly. The objective is straightforward: Make mechanistic pharmacology easier to access, revisit, and apply across research teams. Short conceptual breakdowns Focused receptor theory discussions Clear explanations reinforcing disciplined interpretation As the archive grows, it becomes a searchable extension of Terry’s teaching — designed for repeated exposure rather than one-time viewing. Subscribe to stay current as new videos are released: ▶️ https://www.youtube.com/@TerryPharmacologyCorner New White Paper on GPCR Biased Signaling Terry Kenakin, Ph.D., Professor of Pharmacology at the University of North Carolina School of Medicine, has authored a new white paper in collaboration with Eurofins DiscoverX: Assess GPCR Biased Signaling of Agonists Using Functional Cell-Based Assays The paper explores: Detection and quantification of signaling bias Influence of biased signaling on therapeutic profiles Application of quantitative tools such as transduction coefficients (log(τ/KA) or log(max/EC50)) Systematic comparison of biased agonists using modern functional assays For scientists working in GPCR programs, this connects functional assay data directly to translational decision-making — moving beyond descriptive bias claims toward quantitative rigor. Access the white paper here Why Terry’s Pharmacology Corner Mechanistic understanding evolves. What appears settled under one experimental condition may require refinement under another. What seems definitive during early screening can shift as assay systems, receptor expression levels, or kinetics change. Pharmacology does not drift because data are missing. It drifts when interpretation becomes casual. Terry’s Pharmacology Corner provides a structured environment to maintain interpretive discipline: Weekly advanced pharmacology lectures Monthly live AMAs for real-time scientific discussion A continually expanding on-demand archive Sustained exposure to quantitative receptor theory and mechanistic reasoning The value lies not in a single explanation, but in preserving rigor as programs mature. Forty years of pharmacological expertise — organized into a year-round framework for serious GPCR scientists. Stay in the Know If you want updates on future AMAs, new YouTube releases, white papers, and ongoing pharmacology insights, join Terry Kenakin’s Brief . Concise. Focused. Mechanistic. 👉 Sign up here Continue the Work Live sessions are one layer. Sustained exposure is where judgment sharpens. If you want structured, year-round access to Terry’s full library — including advanced lectures, archived AMAs, and quantitative pharmacology deep dives: 👉 Access Terry’s Corner Free for 7 Days Strengthen Your Mechanistic Thinking

👉 In early-stage biotech, activity often feels like strategy. The platform is advancing, multiple indications are progressing, a grant application is underway, and early partnership conversations are taking shape. At the same time, the team is preparing for biotech fundraising. On the surface, this looks like a strength. There is movement across the board. Each initiative has logic behind it. Each program appears to increase optionality and reduce risk. 👉 This is where strategic overload begins. Strategy is defined by the clarity of the commitment you make. When too many priorities advance in parallel, focus starts to diffuse. Resources stretch. Decision-making slows. The narrative becomes broader but less decisive. The organization feels busy, yet something subtle shifts. No single milestone clearly dominates. No single value inflection point anchors the story. Internally, this feels manageable. Externally, especially in biotech fundraising, it signals hesitation. 👉 The real cost of strategic overload in biotech is not complexity. It is a diluted commitment. And diluted commitment quietly shapes investor perception long before the first pitch meeting ever takes place. Real strategy begins when ambition meets discipline and leadership chooses where to concentrate energy before biotech fundraising. When Everything Is Strategic, Nothing Is Decisive 👉 Strategic overload starts with reasonable decisions. A second indication looks promising. A platform application opens a larger market. A grant opportunity aligns with ongoing research. A potential partner shows interest. Each move can be justified. Each initiative appears to strengthen the company ahead of biotech fundraising. Individually, these choices make sense. Collectively, they create diffusion. ✅ Strategy is the concentration of commitment. In early-stage biotech, resources are finite. Capital is limited. Leadership attention is stretched. When multiple programs advance at the same time, trade-offs become implicit instead of explicit. Nothing is formally deprioritized. Nothing is clearly paused. Everything remains alive. This creates a subtle but powerful shift. Milestones no longer build toward a single dominant value inflection point. Instead, they scatter across parallel tracks. The organization becomes efficient at managing activity, but less effective at signaling conviction. 👉 Conviction requires exclusion. Without exclusion, the company appears broad but not decisive. The scientific ambition may be impressive, yet the strategic narrative loses sharpness. Internally, this feels like diversification. Externally, especially in biotech fundraising, it feels like hesitation. The danger is not visible chaos. It is strategic ambiguity. 👉 And ambiguity is expensive long before it shows up in a term sheet. How Strategic Overload Weakens Biotech Fundraising Signal 👉 Biotech fundraising is not only an evaluation of science. It is an evaluation of focus. Investors are not just asking whether the data is strong. They are assessing whether the company knows exactly where it is going and why. When strategic overload sets in, that clarity begins to erode. The problem is not that there are multiple programs. The problem is that no single program clearly dominates the capital narrative. 👉 Biotech fundraising rewards concentrated signal. Strategic overload produces a diluted signal. When too many priorities move in parallel, several things happen at onc e: 👉 The primary value inflection point becomes unclear 👉 Capital allocation appears fragmented 👉 The development timeline looks crowded rather than sequenced 👉 The story shifts from decisive execution to optional exploration 👉 The perceived execution risk increases None of these issues is dramatic on its own. Together, they create hesitation. From the outside, investors start to ask subtle questions. What is the real bet? Which milestone truly changes the company’s valuation? If capital is deployed today, where does it concentrate and why? If the answers are layered across multiple initiatives, confidence weakens. 👉 Biotech fundraising momentum depends on a visible throughline. That throughline is not a slide in a deck. It is the structural alignment between capital, milestones, and narrative. When resources are spread across too many initiatives, demonstrating alignment becomes harder. 👉 Strategic overload does not make a company look incompetent. It makes it look uncertain. And uncertainty, even when the science is strong, slows biotech fundraising more than most founders expect. Commitment over complexity. Strategic focus strengthens biotech fundraising long before investor conversations begin. Why Founders Rationalize Strategic Overload 👉 Strategic overload rarely feels like a mistake. It feels responsible. Founders in biotech operate under real pressure. Scientific opportunity is rarely linear. Platform technology invites expansion. Early data can point in multiple promising directions. At the same time, boards expect growth, grants require alignment, and potential partners introduce new possibilities. Saying yes often feels safer than saying no. Pursuing multiple paths creates the perception of diversification. If one program slows, another might accelerate. If one indication underperforms, another could generate traction. In the short term, this approach appears to reduce risk and strengthen the story ahead of biotech fundraising. 👉 But diversification at the strategy level is not the same as diversification in a portfolio. A startup is not a fund. It does not have unlimited capital, parallel leadership teams, or independent risk pools. Every additional initiative competes for the same executive attention, the same scientific bandwidth, and the same capital base. What begins as intelligent expansion gradually becomes structural strain. Founders often justify this strain through ambition. The science supports it. The data is promising. The market opportunity is real. Letting go of a program can feel like abandoning potential value. Yet the hardest strategic decisions are rarely about starting something new. They are about choosing what not to pursue. 👉 Strategic discipline requires visible trade-offs. Without explicit trade-offs, priorities accumulate. And when priorities accumulate, clarity declines. That decline may not disrupt daily operations, but it quietly weakens positioning long before biotech fundraising conversations begin in earnest. 👉 Strategic overload persists not because leaders lack intelligence, but because focus demands constraint. And constraint feels uncomfortable in an environment built on discovery. Rebuilding Strategic Discipline Before the Next Biotech Fundraising Cycle 👉 Strategic overload is not solved by better storytelling. It is solved by structural decisions. By the time biotech fundraising begins, investors are not only evaluating data. They are evaluating the architecture of your strategy. They want to see that capital will accelerate a clear thesis, not sustain a collection of parallel experiments. 👉 Strategic discipline must be visible in how the company allocates attention, capital, and sequencing. Before the next biotech fundraising cycle, leadership teams should pressure test their structure with uncomfortable clarity. 1️⃣ Identify the single dominant value inflection point. Which milestone most meaningfully changes the company's valuation? If it succeeds, does it materially strengthen your negotiating position? 2️⃣ Define the primary capital concentration zone. Where will the majority of new capital be deployed, and why? If capital appears evenly distributed, focus is likely diluted. 3️⃣ Clarify the sequencing logic. Are programs advancing because they are strategically ordered, or because they were never explicitly deprioritized? 4️⃣ Articulate the explicit trade-offs. What did you decide not to pursue to strengthen the main thesis? If nothing is clearly paused, the strategy is likely overloaded. 5️⃣ Stress test the narrative under investor scrutiny. Can the entire strategy be explained through one coherent throughline, or does it require layered justifications for multiple parallel bets? These questions are not cosmetic. They expose whether the company is organized around conviction or around optionality. 👉 Biotech fundraising rewards conviction backed by disciplined sequencing. When strategic discipline is present, the story tightens. Capital deployment becomes easier to defend. Milestones reinforce one another instead of competing for attention. Execution risk appears lower because effort is concentrated. 👉 Strategic overload, by contrast, forces founders to defend breadth. Strategic discipline allows them to defend depth. The difference is subtle internally. Externally, especially in biotech fundraising, it is decisive. Strategic Takeaway Strategic overload does not destroy a biotech company. It diffuses it. The danger is not visible failure. It is a diluted commitment. 👉 Biotech fundraising reflects the structure of your strategy long before you start pitching. If capital, milestones, and narrative do not point in the same direction, investors feel it immediately. 👉 Strategy is not defined by how much you pursue. It is defined by what you are willing to exclude. ✅ Focus is commitment. Ready to Break Your Bottlenecks? If you're feeling the friction, indecision, misalignment, or slow momentum, it's not just operational. It's strategic. Attila runs focused strategy consultations for biotech founders who are ready to lead with clarity, not just react to pressure. Whether you're refining your narrative, making tough trade-offs, or simply feeling stuck, this session will help you get unstuck quickly. 👉 Book a 1:1 consult and start building the mindset your company actually needs.

Discovery programs rarely fail because of one experiment. They stall when chemistry, modeling, and pharmacology drift apart. This week, we focus on integration — how to align scientific disciplines before costly translational decisions are made. Breakthroughs this week: 12th Adhesion GPCR Workshop (Düsseldorf, Sept 16–18, 2026); Free fatty acid receptor 2 allosterism is defined by cellular context; Conformational biosensors delineate endosomal G protein regulation by GPCRs. Dr. GPCR University Masterclass — Integrated GPCR Discovery in Practice Dr. GPCR University has been reorganized into a structured, navigable learning framework — and ten reformatted masterclasses are now live in this new architecture. These sessions span foundational pharmacology, receptor biology, modeling, translational strategy, and advanced GPCR decision logic. Each has been redesigned to function as part of a connected curriculum — not isolated content. All masterclasses — past and upcoming — are included with Premium Membership. New courses are delivered live, giving members the opportunity to ask questions directly to the instructors. Recordings are then made available inside the University library for continued access. Why this matters: Live engagement plus permanent access.  Ask your questions in real time — then revisit the material anytime. Structured continuity.  Move through a cohesive GPCR discovery framework, not disconnected lectures. Growing depth.  As new masterclasses launch, your access expands automatically. On March 12, the University returns live with a half-day session focused on integrated GPCR discovery across purinergic programs. Full details will be released soon. Faculty and their immediate teams receive one year of complimentary Premium Membership. Explore Dr. GPCR Masterclass ➤ Eurofins DiscoverX Partnership — Tools and Insight for GPCR Drug Discovery Modern GPCR discovery depends on more than hypotheses. It depends on infrastructure. We are thrilled to have entered a strategic partnership with Eurofins DiscoverX , a global provider of GPCR assay platforms and translational biology services covering more than 90% of the human GPCRome. Their capabilities span cAMP, β-arrestin recruitment, receptor internalization, calcium flux, ligand binding, and integrated discovery support — systems trusted across pharma, biotech, and regulatory programs. This partnership connects advanced assay and biology capabilities with the scientists and organizations positioned to use them — strengthening the bridge between platform expertise and program execution. Why this deserves attention: Assay breadth matters.  Platform selection shapes interpretation. Infrastructure influences velocity.  Scalable systems reduce downstream friction. Field alignment matters.  Industry-grade tools signal maturation of GPCR drug discovery. 👉 Read the Partnership Announcement ➤ Dr. GPCR Podcast — Lipid Rafts, Bitter Taste Receptors, and Context-Dependent Signaling In this episode of the DrGPCR Podcast, Keyvan Sedaghat joins the conversation to explore how membrane compartmentalization shapes GPCR signaling. From dopamine D1 receptor desensitization and GRK isoform specificity to lipid raft biology, the discussion highlights how membrane context reshapes receptor behavior. The episode also explores the open-access 7TMR-Raft database cataloguing GPCR–lipid raft associations and the expanding therapeutic landscape of extra-oral bitter taste receptors, including oncology implications. A recurring theme emerges: computational prediction is powerful — but wet-lab validation remains essential. As AlphaFold and molecular dynamics simulations accelerate hypothesis generation, disciplined experimental confirmation becomes even more critical. Why this matters: Membrane context changes signaling outcomes. Bitter taste receptors extend beyond taste biology. Prediction without validation creates risk. 👉 Listen to the Full Episode ➤ Why Dr. GPCR Premium Membership Gives You an Edge GPCR drug discovery is accelerating — across obesity, CNS, oncology, inflammation, and metabolic disease. Data volume is rising. Platform complexity is expanding. Interpretation risk is increasing. Dr. GPCR operates as a membership-based, nonprofit initiative — built to strengthen the GPCR field through structured access, curated intelligence, and connected expertise. Premium Membership unlocks: Masterclass  — Live and on-demand expert-led sessions, fully integrated into Premium. Weekly News  — Curated industry developments, classified publications, and signal-focused intelligence. Job Listings  — GPCR-specific career opportunities across academia, biotech, and pharma. GPCR Events  — Priority tracking of conferences and specialized meetings. Community Access  — Ask the Ecosystem, Happy Hour, and visibility across the GPCR network. Premium Members also receive a 50%+ discount on Terry’s Corner — unlocking advanced pharmacology depth and live AMAs with Dr. Terry Kenakin (for a limited time). To strengthen equitable participation across the field: Masterclass instructors and their immediate teams receive complimentary Premium access. Scientists living and working in developing countries can join for $25 per year — permanently set to ensure equitable global access. Institutional and team memberships receive discounted rates to support coordinated participation. This is not a content subscription. It is structured access to a field. It supports scientists refining expertise. It strengthens teams executing discovery programs. It equips leaders making strategic and capital decisions. When decisions compound, fragmented information creates drag. Structured access creates momentum. Premium delivers that — consistently. Join Dr. GPCR Premium — Build Your Structured Advantage ➤

Stay at the Forefront of GPCR Drug Discovery Gain insider methods from the pioneers shaping biased signaling, assay design, and pharmacology—skills you won't find in any textbook or paper. ⧖ Hours of Expert Training ↓ Downloadable Resources ◕ New Courses added regularly + All included in Premium Go Premium! Explore the Masterclasses Full classes require Premium. Filter by Category Filter by Level Filter by Instructor Watch Now Terry Kenakin Decoding Drug Action Watch Now Terry Kenakin Seeing is Believing: Assaying Drug Action Coming Soon Terry Kenakin The Allosteric Advantage Watch Now Sam Hoare CRC Super-User: Your Data Advantage Watch Now Terry Kenakin The Art of Antagonism Coming Soon Sam Hoare The Agonist Effect: A Story of Bias Watch Now Terry Kenakin Unlocking Agonist Behavior Coming Soon Sam Hoare The Antagonist's Grip Coming Soon Sam Hoare The Dynamic Allosteric Effect 1 2 1 ... 1 2 ... 2 Learn directly from world leaders in GPCR research Access exclusive training from the scientists shaping the future of GPCR drug discovery Dr. Sam Hoare Pharmechanics GPCR signaling & biased agonism expert regularly consulted by top pharma companies for assay design strategies. Pioneer in quantitative pharmacology methods. Dr. Yamina Berchiche Dr. GPCR & Yamina's Corner Community builder for scientists with expertise in GPCR project strategy and translational applications. Dr. Terry Kenakin Terry's Corner Author of 'A Pharmacology Primer', the definitive GPCR reference used by labs worldwide. Former GSK principal research investigator with 40+ years of experience. Unlock All GPCR Masterclasses 🔥 Upgrade to Premium Premium Yearly $499 $ 499 Every year 🚀 Everything you need to master GPCR science — in one membership. Valid until canceled Join Premium Now 🎓 Full GPCR University + 🔬 200+ expert talks 🗞️ Weekly research, careers & event intelligence 🤝 Members-only networking, AMAs & matchmaking 💡 Support open resources for the global GPCR field 🧠 Designed for researchers at every career stage 🚀 Don’t just keep up — lead the way. 🔒 Grandfather Guarantee, your rate never increases What others are saying Dr. Hoare is very experienced in the field. What came as a pleasant surprise was how didactical and well-thought-out his course was—highly recommended. The really unexpected was that the Q&A sessions reached the highest level—beyond excellent. I am a convert! I will keep Dr. GPCR and the offered resources in my work sphere Anonymous Thank you for bringing this course with Dr. Kenakin. I wish Dr. GPCR the best for the sake of promoting more educational opportunities that are sorely needed in the field Anonymous The content had enough depth to satisfy the hunger for theory while being full of practical knowledge Anonymous The best pharmacology teacher teaming up with the best GPCR community platform to help train and inspire the next generation of scientists. Also super-valuable for those of us learning how to teach pharmacology Anonymous Dr. Hoare's extensive and elaborative explanation of the topics at hand was excellent and very digestible. Thoroughly enjoyed learning from him Anonymous Dr. Kenakin is a leading expert in the field. Aside from his vast experience in drug development, not to mention his extensive publication record, Dr. Kenakin is a masterful teacher and communicator. Anonymous Frequently Asked Questions What is a GPCR Masterclass? A deep-dive training session led by top GPCR scientists, covering pharmacology, signaling, assays, and drug discovery. Each masterclass focuses on practical methods you can apply immediately to your research. Who should join? PhD students, postdocs, biotech/industry scientists, and anyone working with GPCRs who wants to accelerate their research and avoid common pitfalls that waste time and resources. How do I access the masterclasses? Premium members get unlimited, on-demand access to all masterclasses. Watch on any device, anytime. All content is available immediately after joining. Can I preview before joining? Yes – every course includes a free trailer that gives you a taste of the content and teaching style. How do I fit this in my schedule? Each masterclass is designed as a focused 60-90 minute session that you can watch in one sitting or break into smaller segments. Many members watch during lunch breaks or dedicate one evening per week to professional development. What makes your courses different from reading books or articles on PubMed? Our courses offer direct methods, shortcuts, and case studies from experts that you won't find in books or articles on PubMed. We reveal the practical 'how' behind successful experiments, saving you months of trial and error. The GPCR Field Is Advancing Fast – Don't Fall Behind Stay ahead in drug discovery with insights from the world's top GPCR experts. Get Access Today!

Advanced GPCR webinars for pharmacologists and biotech scientists. Live Q&A. Deep mechanistic insight. Reserve your seat. Live GPCR Webinars with the World’s Leading Experts. Learn Faster. Ask Directly. Stay Ahead. Deep-dive sessions focused on real pharmacology, real drug discovery challenges, and real translational insight. * Created by scientists, for scientists 👉 Save Your Spot The Dr. GPCR Webinar Series was created to accelerate GPCR research by connecting scientists directly with leaders in pharmacology, structural biology, drug discovery, and translational science. What makes these webinars different? 🧠 Deep Mechanistic Focus Not “overview talks.” Real models, real data, real debate. 🔬 Drug Discovery Relevance From receptor theory to clinical translation. 🎙️ Direct Access to Experts Live Q&A. Ask what you actually struggle with. 🌍 Global GPCR Community Engage with peers across academia and industry. Free GPCR Webinars Discovery/application angle Fluorescent Probes for GLP-1R and GIPR Imaging: From Cell Assays to In Vivo Systems Speakers Dr. Johannes Broichhagen - Junior Group Leader Dr. David Hodson Learning Outcome: Understand the design and selectivity of LUXendin and daLUXendin probes for GLP-1R and GIPR labeling Apply these probes across imaging workflows from live cells to in vivo systems Choose the right probe for your experimental context Handle, reconstitute, and store fluorescent probes correctly for consistent results Interpret receptor localization and nanodomain data in complex biological systems March 3, 2026 at 3:00:00 PM 📆 Reserve Your Spot Watch Recording 1 1 ... 1 ... 1 Frequently asked questions What are GPCR webinars? GPCR webinars are live online scientific sessions focused on G protein-coupled receptor (GPCR) biology, pharmacology, signaling, and drug discovery. Each session explores mechanistic models, translational challenges, and real-world therapeutic implications. These webinars are designed for scientists who want deep, data-driven discussion rather than surface-level overviews. Who should attend these GPCR pharmacology webinars? These webinars are ideal for: • GPCR pharmacologists • Medicinal chemists working on receptor targets • Structural biologists • Translational scientists • Biotech and pharmaceutical researchers • Postdoctoral fellows and graduate researchers entering drug discovery If you work directly with receptor systems, ligand design, efficacy modeling, or signaling pathways, these sessions are built for you. Are these GPCR webinars suitable for industry scientists? Yes. The content is highly relevant for biotech and pharmaceutical scientists. Topics frequently address: • Receptor efficacy and bias • Allosteric modulation • PK/PD relationships • Irreversible binding and safety considerations • Translational pharmacology challenges The discussions are grounded in practical drug discovery, not just academic theory. How are these different from academic seminars or conferences? Most academic seminars focus on a single dataset or publication. These GPCR webinars focus on conceptual frameworks, models, and translational insight that apply across programs. Unlike large conferences, the live format allows direct interaction, questions, and scientific debate in real time. The goal is not presentation — it is scientific advancement. Are the webinars live or pre-recorded? The sessions are delivered live to allow direct Q&A with the speaker. Live participation gives you the opportunity to ask technical questions and engage in discussion with other scientists in the GPCR community. Selected recordings may be available afterward through the Dr. GPCR platform. Do I need prior knowledge of GPCR pharmacology? These webinars are designed for scientists with foundational knowledge in receptor pharmacology, signaling, or drug discovery. While some sessions may introduce key concepts, the overall level is advanced and assumes familiarity with pharmacological models and terminology. What topics are typically covered in GPCR webinars? Topics may include: • Receptor efficacy and operational models • Allosteric modulators (PAMs and NAMs) • Biased agonism • Dose–response modeling • Calcium and signaling assays • Drug–receptor kinetics • Translational pharmacology strategies • GPCR structure–function relationships Each session focuses on mechanistic clarity and practical application. Are these GPCR webinars free? Yes. All live GPCR webinars are free to attend. To receive early notifications, event reminders, and priority updates, you can join the Dr. GPCR Ecosystem as a free member. If you would like to go deeper beyond the live sessions, you can explore the full GPCR educational library inside Dr. GPCR University.(https://www.ecosystem.drgpcr.com/gpcr-university) Will attending help with continuing education or professional development? Yes. These webinars are designed to support ongoing scientific development in GPCR pharmacology and drug discovery. They provide exposure to current thinking, advanced modeling approaches, and expert interpretation of complex receptor behavior. For researchers working in biotech, pharma, or academia, this type of continuing education can strengthen both technical expertise and strategic thinking. How often are new GPCR webinars added? New live GPCR webinars are added regularly as part of the Dr. GPCR Ecosystem’s ongoing educational initiative. Upcoming sessions are announced in advance and updated on this page. Where can I find advanced GPCR training online? Dr. GPCR provides live GPCR webinars, masterclasses, and in-depth educational resources focused specifically on receptor pharmacology and drug discovery. These programs are designed for scientists seeking advanced, mechanism-focused training in GPCR biology. These sessions are part of a larger mission: building the most trusted home for GPCR scientists worldwide. Join the Next Live Session Be in the room when the science moves forward. 👉 Reserve Your Spot Now

< Back to Webinars Discovery/application angle Fluorescent Probes for GLP-1R and GIPR Imaging: From Cell Assays to In Vivo Systems This is placeholder text. To change this content, double-click on the element and click Change Content. 📅 March 3, 2026 at 3:00:00 PM 🤝 Dr. GPCR x Celtarys Reserve Your Seat! Interrogating Incretin Receptor Biology Across Biological Complexity GLP-1 and GIP receptors have emerged as central targets in metabolic medicine, yet their precise localization, nanodomain organization, and functional engagement within complex biological systems remain incompletely understood. Fluorescent chemical probes offer one of the most direct approaches for investigating receptor distribution and dynamics in native contexts — without relying on receptor overexpression or genetic modification. This webinar introduces two families of advanced fluorescent probes developed specifically for working with endogenous GLP-1R and GIPR across a range of biological complexity. Attendees will gain a technical understanding of probe design, selectivity, and validated applications — as well as practical guidance on handling, reconstitution, dilution, and storage to support immediate laboratory deployment. LUXendin Family Red and far-red fluorescent GLP-1R antagonists derived from Exendin4(9–39). Enable high-specificity labeling of endogenous GLP-1R in live and fixed cells, pancreatic islets, and whole-organ preparations — without triggering receptor activation. Available across multiple spectral ranges for confocal, super-resolution, and intravital imaging. daLUXendin Family Fluorescent dual agonists for both GLP-1R and GIPR (daLUXendin544+ and daLUXendin660+), structurally related to tirzepatide. Enable simultaneous visualization of endogenous receptor localization and nanodomain organization in pancreatic islet cells and neural sites of action in vivo. Speaker Introductions Celtarys Research Celtarys develops and commercializes fluorescent chemical tools and related screening services that enable fluorescence-based methods across drug discovery. The company's portfolio is built around high-affinity, selective fluorescent ligands for GPCRs, supporting researchers working at the interface of chemical biology and pharmacology. Broad GPCR fluorescent ligand portfolio across multiple receptor families Fluorescence Polarization, HTRF, and High-Content Screening formats Fluorescence microscopy and flow cytometry applications Screening services using proprietary probes in living cells Custom chemical development for probe and ligand creation Dr. GPCR Dr. GPCR is a membership-based nonprofit ecosystem dedicated to advancing GPCR-targeted drug discovery. It provides curated industry intelligence, expert-led masterclasses, and structured engagement opportunities for scientists and biotech leaders working across pharmacology, translational research, and therapeutic development. Curated intelligence on GPCR drug discovery trends and developments Expert-led webinars and masterclasses with leading researchers Structured networking for scientists and biotech professionals Nonprofit model — community-first, member-driven Free membership tier available About the Organizers Celtarys Research Celtarys develops and commercializes fluorescent chemical tools and related screening services that enable fluorescence-based methods across drug discovery. The company's portfolio is built around high-affinity, selective fluorescent ligands for GPCRs, supporting researchers working at the interface of chemical biology and pharmacology. Broad GPCR fluorescent ligand portfolio across multiple receptor families Fluorescence Polarization, HTRF, and High-Content Screening formats Fluorescence microscopy and flow cytometry applications Screening services using proprietary probes in living cells Custom chemical development for probe and ligand creation Dr. GPCR Dr. GPCR is a membership-based nonprofit ecosystem dedicated to advancing GPCR-targeted drug discovery. It provides curated industry intelligence, expert-led masterclasses, and structured engagement opportunities for scientists and biotech leaders working across pharmacology, translational research, and therapeutic development. Curated intelligence on GPCR drug discovery trends and developments Expert-led webinars and masterclasses with leading researchers Structured networking for scientists and biotech professionals Nonprofit model — community-first, member-driven Free membership tier available Previous Webinar Next Webinar Don’t Miss the Next Live Session Dr. GPCR membership gives you access to all upcoming live, interactive webinars. Free. Takes less than a minute to join. Cancel anytime. Sign Up for Free